


IN THE CLAIMS:

1. (Withdrawn) Compounds of formula I :



wherein


$R^1 = \text{H}$, or $\text{C}_1\text{-C}_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $=\text{CHR}^3$, -
 $\text{C}(\text{O})\text{OR}^3$, $-\text{C}(\text{O})\text{R}^3$, $-\text{CH}_2\text{C}(\text{O})\text{OR}^3$, $-\text{CH}_2\text{C}(\text{O})\text{NHR}^3$, where R^3 is H or $\text{C}_1\text{-C}_{10}$ alkyl, cycloalkyl, or
alkenyl;

$\text{R}^2 = \text{C}_1\text{-C}_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;


$\text{X}^1 = \text{NHR}^4$, where R^4 is H, $\text{C}_1\text{-C}_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,
the R^4 group optionally containing a carbonyl group, a carboxyl group, a carboxamide group,
an alcohol group, or an ether group, the R^4 group further optionally containing one or more
halogen atoms.

2. (Withdrawn) The compounds of claim 1, wherein R^1 is H, or $\text{C}_1\text{-C}_{10}$ alkyl, cycloalkyl,
alkenyl, aryl, arylalkyl, or alkylaryl, or $=\text{CH}_2$.
3. (Withdrawn) The compounds of claim 2, wherein R^1 is $-\text{CH}_3$ or $=\text{CH}_2$.


4. (Withdrawn) The compounds of claim 3, wherein the compound is selected from the group consisting of:



5. (Withdrawn) The compounds of claim 1, wherein R^4 is $-\text{CH}_2\text{C}(\text{O})\text{OR}^5$ or $-\text{CH}_2\text{C}(\text{O})\text{NHR}^5$, where R^5 is H, $\text{C}_1\text{-C}_{10}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
6. (Withdrawn) The compounds of claim 1, wherein the compound is selected from the group consisting of:



7. (Withdrawn) Compounds of formula II:



II

wherein

$R^6 = H$, or C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $-C(O)OR^8$, $-C(O)R^8$, $-CH_2C(O)OR^8$, $-CH_2C(O)NHR^8$, where R^8 is H or C_1 - C_{10} alkyl, cycloalkyl, or alkenyl;

$R^7 = C_1$ - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

$X^2 = NHR^9$, where R^9 is H , C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R^9 group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the R^9 group further optionally containing one or more halogen atoms;


with the proviso that when R^6 is $-CH_3$, and R^7 is $n-C_{13}H_{27}$, X^2 is not $-NHC_2H_5$.

8. (Withdrawn) The compounds of claim 7, wherein R^6 is C_1 - C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

9. (Withdrawn) The compounds of claim 8, wherein R^6 is $-CH_3$.

10. (Withdrawn) The compounds of claim 7, wherein R^9 is $-CH_2C(O)OR^{10}$ or $-CH_2C(O)NHR^{10}$, where R^{10} is H , C_1 - C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

11. (Withdrawn) Compounds of formula IV:



IV

wherein

$R^{16} = H$, or C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $-C(O)OR^{18}$, $-C(O)R^{18}$, $-CH_2C(O)OR^{18}$, $-CH_2C(O)NHR^{18}$, where R^{18} is H or C_1 - C_{10} alkyl, cycloalkyl, or alkenyl;

$R^{17} = C_1$ - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

$X^4 = OR^{19}$, where R^{19} is C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R^{19} group optionally containing a carbonyl group, a carboxyl group, a carboxamide group, an alcohol group, or an ether group, the R^{19} group further optionally containing one or more halogen atoms;


with the proviso that when R^{16} is $-CH_3$ and R^{19} is $-CH_3$, then R^{17} is not substituted or unsubstituted phenyl, $-nC_3H_7$, $-nC_5H_{11}$, $-nC_{13}H_{27}$, and with the further proviso that when R^{16} is H and R^{19} is $-CH_3$, then R^{17} is not substituted or unsubstituted phenyl or $-CH_3$, and when R^{16} is H and R^{19} is $-CH_2CH_3$, then R^{17} is not $-iC_3H_7$, or substituted or unsubstituted phenyl.

12. (Withdrawn) The compounds of claim 11, wherein R^{16} is C_1 - C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

13. (Withdrawn) The compounds of claim 12, wherein R^{16} is $-CH_3$.

14. (Withdrawn) The compounds of claim 11, wherein R^{19} is $-CH_2C(O)OR^{20}$ or $-CH_2C(O)NHR^{20}$, where R^{20} is C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

15. (Previously Presented) Compounds of formula V:



V

wherein

$R^{21} = C_2-C_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $=CHR^{23}$, $-C(O)OR^{23}$, $-C(O)R^{23}$, $-CH_2C(O)OR^{23}$, $-CH_2C(O)NHR^{23}$, where R^{23} is H or C_1-C_{10} alkyl, cycloalkyl, or alkenyl, except when R^{21} is $=CHR^{23}$, R^{23} is not H;


$R^{22} = C_2-C_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

with the proviso that when R^{21} is $-COOH$, then R^{22} is not $-nC_5H_{11}$, or $C_{13}H_{27}$, and with the further proviso that when R^{21} is $-CH_2COOH$, then R^{22} is not $-CH_2CH_3$, or $-iC_5H_{11}$.

16. (Previously Presented) The compounds of claim 15, wherein R^{21} is C_2-C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

17. (Cancelled)

18. (Withdrawn) Compounds of formula VI:



VI

wherein:


$R^{24} = C_2-C_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $-C(O)OR^{26}$, $-C(O)R^{26}$, $-CH_2C(O)OR^{26}$, $-CH_2C(O)NHR^{26}$, where R^{26} is H or C_1-C_{10} alkyl, cycloalkyl, or alkenyl;

$R^{25} = C_1-C_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

with the proviso that when R^{24} is $-COOH$, then R^{25} is not $-CH_3$, $-nC_5H_{11}$, or $C_{13}H_{27}$, and with the further proviso that when R^{24} is $-CH_2COOH$, then R^{25} is not $-CH_3$, $-CH_2CH_3$, or $-iC_5H_{11}$.

19. (Withdrawn) The compounds of claim 18, wherein R^{21} is C_2-C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

20. (Previously Presented) Compounds of formula VII:




wherein

$R^{27} = C_{12}$ alkyl, C_{14} alkyl, $C_{16}-C_{20}$ alkyl.

21 – 22. (Cancelled)

23. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula IX:



IX

R^{29} = H, or C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $=CHR^{31}$,
 $-C(O)OR^{31}$, $-C(O)R^{31}$, $-CH_2C(O)OR^{31}$, $-CH_2C(O)NHR^{31}$, where R^{31} is H or C_1 - C_{10} alkyl,
 cycloalkyl, or alkenyl;

R^{30} = C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;


X^5 = $-OR^{32}$, or $-NHR^{32}$, where R^{32} is H, C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl,
 or alkylaryl, the R^{32} group optionally containing a carbonyl group, a carboxyl group, a
 carboxyamide group, an alcohol group, or an ether group, the R^{32} group further optionally
 containing one or more halogen atoms;

with the proviso that when R^{29} is $=CH_2$, then X^5 is not OH.

24. (Withdrawn) The pharmaceutical compositions of claim 23, wherein R^{29} is C_1 - C_{10} alkyl,
 cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or $=CH_2$.

25. (Withdrawn) The pharmaceutical compositions of claim 24, wherein R^{29} is $-CH_3$ or
 $=CH_2$.

26. (Withdrawn) The pharmaceutical compositions of claim 23, wherein R³² is -CH₂C(O)OR³³ or -CH₂C(O)NHR³³, where R³³ is C₁-C₁₀ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
27. (Withdrawn) The pharmaceutical compositions of claim 23, where R²⁹ is -C₆H₁₃ or -C₈H₁₇.
28. (Withdrawn) The pharmaceutical compositions of claim 23, wherein the compound is selected from the group consisting of:



29. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 1.
30. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 7.
31. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 11.


32. (Original) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 15.

33. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 18.

34. (Original) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 20.

35. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 22.

36. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to Formula III:



III

wherein

$R^{11} = \text{H, or } C_1\text{-}C_{20} \text{ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, } =\text{CHR}^{13},$
 $-\text{C(O)OR}^{13}, -\text{C(O)R}^{13}, -\text{CH}_2\text{C(O)OR}^{13}, -\text{CH}_2\text{C(O)NHR}^{13},$ where R^{13} is H or $C_1\text{-}C_{10}$ alkyl, cycloalkyl, or alkenyl;

$R^{12} = C_1\text{-}C_{20} \text{ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl ;}$

$X^3 = OR^{14}$, where R^{14} is C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R^{14} group optionally containing a carbonyl group, a carboxyl group, a carboxamide group, an alcohol group, or an ether group, the R^{14} group further optionally containing one or more halogen atoms.

37. (Withdrawn) The pharmaceutical formulation of claim 36, wherein R^{11} is C_1 - C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or $=CH_2$.

38. (Withdrawn) The pharmaceutical formulation of claim 37, wherein R^{11} is $-CH_3$ or $=CH_2$.


39. (Withdrawn) The pharmaceutical formulation of claim 36, wherein R^{14} is $-CH_2C(O)OR^{15}$ or $CH_2C(O)NHR^{15}$, where R^{15} is C_1 - C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

40. (Withdrawn) A method of inducing weight loss in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.


41. (Withdrawn) The method of claim 40, wherein the subject is a human.

42. (Withdrawn) The method of claim 40, wherein the subject is an animal.

43. (Withdrawn) The method of claim 41, wherein the pharmaceutical composition comprises a compound selected from the group consisting of



44. (Withdrawn) The method of claim 42, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:




45. (Withdrawn) A method of inhibiting growth of cancer cells in an animal or human subject, comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.






46. (Withdrawn) The method of claim 45, wherein the subject is a human.

47. (Withdrawn) The method of claim 45, wherein the subject is an animal.

48. (Withdrawn) The method of claim 46, wherein the pharmaceutical composition comprises a compound selected from the group consisting of



49. (Withdrawn) The method of claim 47, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:


(±)	(±)	(±)	(±)
			
(e)			
			

50. (Withdrawn) A method of stimulating the activity of CPT-1 in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.


51. (Withdrawn) The method of claim 50, wherein the subject is a human.

52. (Withdrawn) The method of claim 50, wherein the subject is an animal.


53. (Withdrawn) The method of claim 51, wherein the compound is:













54. (Withdrawn) The method of claim 52, wherein the compound is:



55. (Withdrawn) A method of inhibiting the activity of neuropeptide-Y in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.
56. (Withdrawn) The method of claim 55, wherein the subject is a human.
57. (Withdrawn) The method of claim 55, wherein the subject is an animal.
58. (Withdrawn) A method of inhibiting fatty acid synthase activity in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.
59. (Withdrawn) The method of claim 58, wherein the subject is a human.
60. (Withdrawn) The method of claim 58, wherein the subject is an animal.
61. (Withdrawn) The method of claim 59, wherein the compound is selected from the group consisting of:




62. (Withdrawn) The method of claim 60, wherein the compound is selected from the group consisting of:

 $\text{H}_3\text{C}(\text{H}_2\text{C})_7\text{CO}_2\text{H}$	 $\text{H}_3\text{C}(\text{H}_2\text{C})_7\text{CO}_2\text{H}$	(±)  $\text{H}_3\text{C}(\text{H}_2\text{C})_7$	 $\text{H}_3\text{C}(\text{H}_2\text{C})_7$
(±)  $\text{H}_3\text{C}(\text{H}_2\text{C})_7$	(±)  $\text{H}_3\text{C}(\text{H}_2\text{C})_7$	(±)  $\text{H}_3\text{C}(\text{H}_2\text{C})_7$	(±)  $\text{H}_3\text{C}(\text{H}_2\text{C})_7$
 $\text{H}_3\text{C}(\text{H}_2\text{C})_7$, and	(±)  $\text{H}_3\text{C}(\text{H}_2\text{C})_7$		


63. (Withdrawn) A method of inhibiting growth of invasive microbial cells in an animal or human subject comprising the administration of an effective amount of a pharmaceutical composition according to claim 23 to said subject.

64 - 65. (Cancelled)

66. (Withdrawn) The method of claim 64, wherein the compound is selected from the group consisting of:



67. (Withdrawn) The method of claim 65, wherein the compound is selected from the group consisting of:



68. (Not Entered)

69. (Previously Presented) Compounds according to claim 15, wherein


R^{21} = cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $=\text{CHR}^{23}$, $-\text{C}(\text{O})\text{OR}^{23}$, $-\text{C}(\text{O})\text{R}^{23}$, $-\text{CH}_2\text{C}(\text{O})\text{OR}^{23}$, $-\text{CH}_2\text{C}(\text{O})\text{NHR}^{23}$, where R^{23} is H or $\text{C}_1\text{-C}_{10}$ alkyl, cycloalkyl, or alkenyl, except when R^{21} is $=\text{CHR}^{23}$, R^{23} is not H ;

R^{22} = $\text{C}_1\text{-C}_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

with the proviso that when R^{21} is $-\text{COOH}$, then R^{22} is not $-\text{C}_{13}\text{H}_{27}$, and with the further proviso that when R^{21} is $-\text{CH}_2\text{COOH}$, then R^{22} is not $-\text{CH}_2\text{CH}_3$, or $-\text{iC}_5\text{H}_{11}$.

70. (Previously Presented) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 69.

71. (Previously Presented) Compounds of formula X:



wherein

$R^{42} = C_2-C_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

72. (Previously Presented) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 71.